<?xml version="1.0" encoding="utf-8" ?>
<INTERACTIONS>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>530-TRIMETHOPRIM.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="TRIMETHOPRIM" rxcui="10829">
<ATC code="J01EA01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="CICLOSPORIN" rxcui="3008">
<ATC code="L04AD01" />
<ATC code="S01XA18" />
</DRUG>
</DRUG2>
<DESCRIPTION>With the trimethoprim (alone or in combination) by oral route: increase of the creatinemia with possible decrease of the blood concentrations of ciclosporin

With trimethoprime (alone or in combination) by IV route: the decrease of the blood concentrations of ciclosporin can be very large with possible loss of all immunosuppressant capacity</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>530-TRIMETHOPRIM.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="TRIMETHOPRIM" rxcui="10829">
<ATC code="J01EA01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="METHOTREXATE" rxcui="6851">
<ATC code="L01BA01" />
<ATC code="L04AX03" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the hematological toxicity of the methotrexate (decrease of its renal excretion as well as inhibition of the dihydrofolate reductase).</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>530-TRIMETHOPRIM.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="TRIMETHOPRIM" rxcui="10829">
<ATC code="J01EA01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="PYRIMETHAMINE" rxcui="9010">
<ATC code="P01BD01" />
<ATC code="P01BD51" />
<ATC code="P01BF04" />
</DRUG>
</DRUG2>
<DESCRIPTION>Megaloblastic anemia, more particularly with strong doses of the two products (deficit of folic acid due to the combination of the two 2-4 diaminopyrimidines)</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Regular CBC and addition of a treatment with folic acid (regular IM injections). </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>530-TRIMETHOPRIM.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="TRIMETHOPRIM" rxcui="10829">
<ATC code="J01EA01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="REPAGLINIDE" rxcui="73044">
<ATC code="A10BX02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of increase of the plasma concentrations of repaglinide due to inhibition of its hepatic metabolism by the trimethoprim</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>If administering these medications together cannot be avoided, strict clinical and biological monitoring. </COMMENT>
</INTERACTION>
</INTERACTIONS>
